{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:48:34Z","timestamp":1720140514549},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.jpba.2012.04.017","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T19:08:32Z","timestamp":1335208112000},"page":"28-35","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Characterization of currently marketed heparin products: Adverse event relevant bioassays"],"prefix":"10.1016","volume":"67-68","author":[{"given":"Cynthia D.","family":"Sommers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Montpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Keire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2012.04.017_bib0005","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/pds.1991","article-title":"Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008","volume":"19","author":"McMahon","year":"2008","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"10.1016\/j.jpba.2012.04.017_bib0010","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1056\/NEJMoa0806450","article-title":"Outbreak of adverse reactions associated with contaminated heparin","volume":"359","author":"Blossom","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2012.04.017_bib0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1749-6632.1987.tb33047.x","article-title":"The activation of the contact system of human plasma by polysaccharide sulfates","volume":"516","author":"Silverberg","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jpba.2012.04.017_bib0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/toxsci\/kfr072","article-title":"Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat","volume":"121","author":"Corbier","year":"2011","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jpba.2012.04.017_bib0025","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa0803200","article-title":"Contaminated heparin associated with adverse clinical events and activation of the contact system","volume":"358","author":"Kishimoto","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2012.04.017_bib0030","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.1016\/j.biomaterials.2010.03.074","article-title":"Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro","volume":"31","author":"Adam","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jpba.2012.04.017_bib0035","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0091270009355158","article-title":"Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin","volume":"50","author":"McKee","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2012.04.017_bib0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1877-1173(10)93017-2","article-title":"Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis","volume":"93","author":"Qian","year":"2010","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jpba.2012.04.017_bib0045","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1056\/NEJMe0803599","article-title":"Heparin comes clean","volume":"358","author":"Schwartz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2012.04.017_bib0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.SRJ05001X","article-title":"The kallikrein-kinin system: current and future pharmacological targets","volume":"99","author":"Moreau","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.jpba.2012.04.017_bib0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bcp.2009.04.012","article-title":"Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins","volume":"78","author":"Li","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2012.04.017_bib0060","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jpba.2009.10.017","article-title":"Analysis of crude heparin by (1)H NMR capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate","volume":"51","author":"Keire","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2012.04.017_bib0065","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1021\/ac200011s","article-title":"Sensitive detection of oversulfated chondroitin sulfate in heparin sodium or crude heparin with a colorimetric microplate based assay","volume":"83","author":"Sommers","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2012.04.017_bib0070","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1021\/ac201412z","article-title":"Detection of possible economically motivated adulterants in heparin sodium and low molecular weight heparins with a colorimetric microplate based assay","volume":"83","author":"Sommers","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2012.04.017_bib0075","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jpba.2010.02.019","article-title":"Assay of possible economically motivated additives or native impurities levels in heparin by 1H NMR SAX-HPLC, and anticoagulation time approaches","volume":"52","author":"Keire","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2012.04.017_bib0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ab.2009.03.009","article-title":"Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products","volume":"388","author":"Bairstow","year":"2009","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2012.04.017_bib0085","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1016\/j.biomaterials.2008.08.024","article-title":"Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants","volume":"29","author":"Tami","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.jpba.2012.04.017_bib0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1054-3589(05)53019-9","article-title":"Immunological activity of chondroitin sulfate","volume":"53","author":"Toida","year":"2006","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.jpba.2012.04.017_bib0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/1076029610392214","article-title":"Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications","volume":"17","author":"Ramacciotti","year":"2011","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.jpba.2012.04.017_bib0100","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1182\/blood-2010-06-292938","article-title":"Heparin modifies the immunogenicity of positively charged proteins","volume":"116","author":"Chudasama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2012.04.017_bib0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00216-010-4220-8","article-title":"Protamine neutralisation of low molecular weight heparins and their oligosaccharide components","volume":"399","author":"Schroeder","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2012.04.017_bib0110","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1021\/ja109699s","article-title":"Analysis of the complex formation of heparin with protamine by light scattering and analytical ultracentrifugation: implications for blood coagulation management","volume":"133","author":"Maurer","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jpba.2012.04.017_bib0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0008-6215(97)10060-X","article-title":"Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation","volume":"306","author":"Maruyama","year":"1998","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.jpba.2012.04.017_bib0120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0196-9781(94)90214-3","article-title":"Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues","volume":"15","author":"Decarie","year":"1994","journal-title":"Peptides"},{"key":"10.1016\/j.jpba.2012.04.017_bib0125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00216-010-4023-y","article-title":"Characterization of currently marketed heparin products: key tests for quality assurance","volume":"399","author":"Keire","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2012.04.017_bib0130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/gb-2006-7-5-216","article-title":"An overview of the serpin superfamily","volume":"7","author":"Law","year":"2006","journal-title":"Genome Biol."},{"key":"10.1016\/j.jpba.2012.04.017_bib0135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","article-title":"Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin","volume":"116","author":"Crowther","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jpba.2012.04.017_bib0140","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/abio.1998.2947","article-title":"Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes","volume":"266","author":"Ramamurthy","year":"1999","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2012.04.017_bib0145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.jpba.2012.04.017_bib0150","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1538-7836.2008.03034.x","article-title":"Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets","volume":"6","author":"Hamad","year":"2008","journal-title":"J. Thromb. Haemost."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708512002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708512002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T17:50:25Z","timestamp":1542995425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708512002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":30,"alternative-id":["S0731708512002142"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2012.04.017","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}